Carlos Alexandre Antunes de Brito1,2,3, André Ricardo Ribas Freitas4, Rodrigo Fabiano Said5, Melissa Barreto Falcão6, Rivaldo Venâncio da Cunha7,8, André Machado Siqueira9, Maria Glória Teixeira10, Guilherme Sousa Ribeiro11,12, Marina Coelho Moraes de Brito2,13, Luciano Pamplona de Góes Cavalcanti14. 1. Universidade Federal de Pernambuco, Departamento de Medicina Clínica, Recife, PE, Brasil. 2. Instituto de Pesquisa Autoimune, Recife, PE, Brasil. 3. Ministério da Saúde do Brasil, Comitê Técnico de Arboviroses, Brasília, DF, Brasil. 4. Faculdade São Leopoldo Mandic, Campinas, SP, Brasil. 5. Organização Panamericana de Saúde, Brasília, DF, Brasil. 6. Universidade Estadual de Feira de Santana, Núcleo de Pesquisa e Extensão em Vigilância à Saúde, Feira de Santana, BA, Brasil. 7. Fundação Oswaldo Cruz, Campo Grande, MS, Brasil. 8. Universidade Federal do Mato Grosso do Sul, Escola de Medicina, Campo Grande, MS, Brasil. 9. Fundação Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, RJ, Brasil. 10. Universidade Federal da Bahia, Instituto de Saúde Coletiva, Salvador, BA, Brasil. 11. Universidade Federal da Bahia, Escola de Medicina, Salvador, BA, Brasil. 12. Fundação Oswaldo Cruz, Instituto Gonçalo Moniz, Salvador, BA, Brasil. 13. Universidade Federal de Pernambuco, Centro de Ciências Médicas, Recife, PE, Brasil. 14. Universidade Federal do Ceará, Escola de Medicina, Departamento de Saúde Comunitária, Fortaleza, CE, Brasil.
Since 2005, chikungunya virus (CHIKV) has caused large outbreaks, with reports of
more than 10 million cases worldwide over the course of a decade
. Although musculoskeletal involvement is the most prevalent symptom in the
disease spectrum, systemic manifestations with involvement of important organs have
also been described
-
.Currently, case classifications of chikungunya based on the intensity and duration of
articular symptoms have been used to guide the clinical management of the joint
manifestations, with little or no emphasis on the severe clinical forms associated
with systemic disease and target organ involvement. Thus, these classifications have
failed to aid health professionals in the detection and early management of severe
cases, which can lead to fatal outcomes and sequelae
.A group of experts decided to review the classification of chikungunya fever cases to
raise awareness to the severe forms of chikungunya with the aim of reducing
mortality, which is aligned with the World Health Organization (WHO)’s goals of
decreasing fatal outcomes of vector-borne diseases by 50% and 75% by 2025 and 2030,
respectively. The proposed classification system will be incorporated into the new
guidelines for the diagnosis and treatment of chikungunya fever of the Brazilian
Ministry of Health, which are already under development.The findings from chikungunya clinical studies and the accumulated experience of
specialists during epidemics in India, the Caribbean, and, most recently, Brazil
support the need for adjustments to the current classifications
. We believe that a revised classification system should be based on an
expanded description of the different clinical presentations of the disease,
expressing the various biological gradients, which should range from mild to severe,
as would be expected for an infectious disease (Evans’ Fifth Postulate). A
classification system encompassing the full disease spectrum will help increase
health professionals’ awareness of the severity and complications associated with
each category, similar to the systems that have been developed for countless other
epidemic infectious diseases. A structured classification system allows the
standardization of treatment according to clinical complexity and severity, guiding
actions such as the definition of the treatment setting based on disease complexity,
ordering of complementary exams, and initiation of therapies.
DISCUSSION
In 2015, a panel of experts revised the classification of chikungunya cases and
proposed four disease categories: acute, atypical, severe acute, and chronic
. Although this proposed classification system represents an important
improvement, it still has limitations, as the main symptom used to categorize the
patients is joint impairment, without focusing on systemic symptoms that can occur.
A study performed in a university hospital in Martinique showed that the current
chikungunya fever classification system produced by the WHO is especially
ineffective for elderly patients. Of the 257 patients older than 65 years with
laboratory confirmation of CHIKV infection with positive reverse transcriptase
polymerase chain reaction results, 42.7% could not be classified in any category of
the current system, and in the group of 109 younger patients (<65 years), 17.4%
could not be classified, showing that this model has limitations. Additionally, in
the group aged 65 years and older, only 8.2% were classified as having the typical
form as defined by the WHO
.Furthermore, the pathophysiological mechanisms of the main arbovirus infections,
including chikungunya, reinforce the concept that the disease is dynamic and that
the impairment of systemic organs (classified as atypical forms) can evolve into
severe forms and become the main cause of death related to CHIKV infections.
Therefore, at any stage, systemic manifestations should represent an important sign
of severity. The atypical and acute severe groups suggested in the 2015 modification
of the classification system represent the same group with different biological
levels of intensity.Several of the terms used in the classification system may need to be revised in the
process of creating a categorization system that can ultimately enable professionals
to detect cases. The term “atypical” refers to that which does not correspond to the
predominant clinical features of chikungunya but rather to a situation that is
unexpected, which minimizes the relevance; however, it is clear that the impairment
of systemic organs is part of the spectrum of the disease, even if it is less
common. Similar patterns have been observed in numerous other epidemic viral
diseases (dengue, yellow fever, and influenza).
Expanded clinical spectrum of the disease
Musculoskeletal manifestations are the most common, and their management is
related to different phases
-
. Chronologically, the spectrum of the disease involves three phases
(acute, postacute, and chronic). Clinically, there are different patterns of
joint manifestations that may be predominantly noninflammatory/musculoskeletal
(mechanical) or inflammatory with arthritis and periarticular manifestations.
Approximately 50% of patients develop chronic joint disease, with important
impairment of their quality of life, and, in many cases, mimicking clinical
patterns of rheumatic diseases such as rheumatoid arthritis (RA), seronegative
spondylarthritis (SpA), fibromyalgia (FM), and undifferentiated
polyarthritis
-
.In addition to musculoskeletal involvement, there are relevant systemic
manifestations with the involvement of important organs. Systemic manifestations
that can evolve with exacerbation mainly affect the nervous, cardiac, pulmonary,
renal, hepatic, endocrine, and vascular systems
-
.In 2016 on Reunion Island, among the 123 cases of severe chikungunya fever, the
main reasons for hospitalization were respiratory failure (19 cases),
cardiovascular decompensation (18), meningoencephalitis (16), severe hepatitis
(11), severe skin lesions (10), and renal failure (7)
.Among the 96 nonpregnant adults enrolled in a study by Bonifay et al. in French
Guiana during the 2014/2015 CHIKV outbreak, 29% of the patients were classified
as having atypical or severe forms, with the most common symptoms being
neurological symptoms (Guillain-Barret syndrome, encephalitis, seizure,
confusion, and stroke), followed by cardiorespiratory failure, hepatitis,
pancreatitis, renal failure, and muscular impairment
.Severe forms of the disease and fatal outcomes have been described as more often
affecting those at the extreme ends of the age spectrum, predominantly elderly
patients, and the presence of comorbidities may contribute to the development of
complications
. However, severe forms have also been described in different age groups
in the absence of associated diseases
-
. In a study of 44 patients with arrhythmia conducted by Economopoulo et
al., 63% had no history of cardiovascular disease, and in 131 patients with
blood glucose level alterations, 20% were diagnosed with diabetes mellitus for
the first time
.The signs and symptoms described in the systemic form of chikungunya fever are
related to the injury of target organs by the disease
-
. In a systematic review of the systemic manifestations associated with
chikungunya, cardiac involvement was reported in 54% of the articles, and the
predominant symptoms were chest pain, fatigue, dyspnea, palpitations, vagal
symptoms (diaphoresis, pallor, and coughing), nausea, dizziness, and
lipothymia/syncope. On physical examination, the findings included tachycardia,
atrial and ventricular premature ectopic beats, crepitation or rhonchi in the
lungs, and tachypnea
.Mehta R et al., in a systematic review of neurological impairment due to
chikungunya, found encephalitis to be the most common complication, followed by
myelopathy, myelitis, and Guillain‐Barré syndrome
. The most common symptoms included headaches, altered sensorium,
lethargy, seizures, weakness, and paresthesia
.Studies conducted first in India and more recently in Brazil reported
significantly higher mortality rates in the months coinciding with chikungunya
outbreaks than in the same period in previous years and the expected rates after
the outbreak. Retrospective analyses in different Latin American countries have
produced similar results, demonstrating a strong temporal association and
potential causality between this surplus mortality and the outbreak
,
.It is possible that the failure to accurately identify the mortality rate
associated with chikungunya is related not only to flaws in the surveillance
system but also, and perhaps mainly, to the lack of an awareness of the
possibility of CHIKV infection as a cause death on the part of doctors. In part,
this can be justified by the limited knowledge of serious systemic
manifestations and possible complications related to CHIKV infection and the
lack of a case classification system that contributes to increasing the
awareness of health professionals about the spectrum of this disease.
RESULTS: A structured classification system based on the clinical spectrum of
the disease
The clinical spectrum of the disease chronologically involves three phases: an
acute phase (up to 14 days), a postacute phase (15 to 90 days), and a chronic
phase (after 3 months). The disease should be classified according to the
clinical spectrum and level of intensity as follows:- “Classic chikungunya”, divided into 3 phases according to the duration of
symptoms: “acute”, “postacute”, and “chronic”; and- “Systemic chikungunya”, divided by severity into “chikungunya with alarm signs”
and “severe chikungunya” (Figure 1).
FIGURE 1:
Proposal of new classification system for chikungunya
cases.
1. Classic chikungunya: The classic form of chikungunya is characterized by
musculoskeletal impairment, which is the most common clinical manifestation of
the disease with an inflammatory component predominantly in the acute phase. The
postacute and chronic phases have different patterns of manifestations that can
involve: (a) localized or diffuse noninflammatory musculoskeletal pain; (b)
arthritis/tenosynovitis (articular or periarticular disease associated with
edema); and (c) neuropathic pain. It is important to emphasize that a patient
can present with a combination of patterns such as arthritis or noninflammatory
musculoskeletal pain associated with neuropathic pain.2. Systemic chikungunya: These forms are characterized by systemic manifestations
resulting from organ impairment that may or may not present simultaneously with
or be preceded by musculoskeletal manifestations. The clinical spectrum involves
systemic organ impairment due to the direct effects of the virus, systemic
inflammatory response, or indirect causes (as a consequence of decompensating
underlying disease). The systemic impairment of organs can involve the
following: cardiovascular (myocarditis, pericarditis, arrhythmia, and
hemodynamic instability); central and peripheral nervous system (encephalitis,
myelitis, meningoencephalitis, stroke, Guillain-Barré syndrome, optic neuritis,
cerebellitis, and rhombencephalitis); pulmonary (pneumonitis); renal
(nephritis); gastrointestinal (upper- and lower-digestive hemorrhage, and acute
hepatitis); others (rhabdomyolysis, inappropriate antidiuretic hormone secretion
syndrome, and adrenal insufficiency); indirect causes due to decompensation of
comorbidities, including preexisting cardiovascular (arterial hypertension and
heart failure), kidney, or lung (COPD and asthma) diseases, or other secondary
causes like pulmonary thromboembolism in patients with joint immobility and
edema (Figure 1).With regard to chronology, these manifestations may occur days or weeks after the
initial symptoms appear. The timing of the event depends on the causes and
organs affected, while the gradient of intensity is classified as chikungunya
with alarm signs or severe chikungunya, which can be identified by the presence
of alarm signs or their aggravation, respectively (Figure 1). Alarm signs manifest when target organs are affected. The
presence of alarm signs should be defined as a separate group, since it
indicates the presence of clinical conditions that can progress with aggravation
and carries the risk of a fatal outcome, necessitating careful medical care and
specialized treatment.In the severe form, the patient experiences aggravation of the
clinical features, with worsening of alarm signs due to organ failure that may
be cardiovascular, neurological, respiratory, renal, and/or hepatic. Signs of
shock represent one of the manifestations of aggravation related to systemic
cardiovascular impairment.
CONCLUSION
We believe that the proposed classification system takes into consideration the
different clinical manifestations of CHIKV infection, thus facilitating the
construction of flowcharts and guiding the development of future clinical guidelines
for addressing the complete spectrum of the disease and increasing awareness of this
spectrum, enabling health care professionals to identify and treat systemic
chikungunya before the development of worse outcomes.
Authors: Luciano Pamplona de Góes Cavalcanti; Luís Arthur Brasil Gadelha Farias; Francisca Kalline de Almeida Barreto; André Machado Siqueira; Guilherme Sousa Ribeiro; André Ricardo Ribas Freitas; Scott C Weaver; Uriel Kitron; Carlos Alexandre Antunes Brito Journal: Am J Trop Med Hyg Date: 2020-02 Impact factor: 2.345
Authors: A Economopoulou; M Dominguez; B Helynck; D Sissoko; O Wichmann; P Quenel; P Germonneau; I Quatresous Journal: Epidemiol Infect Date: 2008-08-11 Impact factor: 2.451
Authors: Philippe Renault; Jean-Louis Solet; Daouda Sissoko; Elsa Balleydier; Sophie Larrieu; Laurent Filleul; Christian Lassalle; Julien Thiria; Emmanuelle Rachou; Henriette de Valk; Daniele Ilef; Martine Ledrans; Isabelle Quatresous; Philippe Quenel; Vincent Pierre Journal: Am J Trop Med Hyg Date: 2007-10 Impact factor: 2.345
Authors: Ravi Mehta; Patrick Gerardin; Carlos Alexandre Antunes de Brito; Cristiane Nascimento Soares; Maria Lucia Brito Ferreira; Tom Solomon Journal: Rev Med Virol Date: 2018-04-19 Impact factor: 6.989
Authors: Thiara Manuele Alves de Souza; Caroline Fernandes-Santos; Jéssica Araújo da Paixão de Oliveira; Larissa Cristina Teixeira Tomé; Victor Edgar Fiestas-Solórzano; Priscila Conrado Guerra Nunes; Gabriel Macedo Costa Guimaraes; Juan Camilo Sánchez-Arcila; Iury Amâncio Paiva; Luís Jose de Souza; Paulo Vieira Damasco; Válber da Silva Frutuoso; Manoela Heringer; Luzia Maria de Oliveira-Pinto; Roberta Olmo Pinheiro; Flavia Barreto Dos Santos; Elzinandes Leal de Azeredo Journal: Pathogens Date: 2022-04-07